After scouring 200 companies’ pipelines, a new biotech firm is launching with one of the most wide-ranging pipelines yet for obesity drug development. Read this story
After scouring 200 companies’ pipelines, a new biotech firm is launching with one of the most wide-ranging pipelines yet for obesity drug development. Read this story
More from STAT | biotechnology Obesity GLP-1 receptor agonist Anti-obesity medication Eli Lilly and Company Biotechnology Medicines Company (The) Startup company Novo Nordisk Metabolic disorder